# Centocor, Inc. clinical trials: 75 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 75 trials with Centocor, Inc. as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Centocor, Inc.: 75 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/centocor-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 75
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 25 newest of 75, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| February 28, 2014 | NCT02074800 | A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in... | Centocor, Inc. | Phase 1 | Completed | Healthy | 145 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02074800) |
| May 30, 2011 | NCT01362153 | A Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Golimumab in Patients With Rheumatoid Arthritis (RA) | Centocor, Inc. | Phase 1 | Completed | Rheumatoid Arthritis | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01362153) |
| February 2, 2011 | NCT01288157 | A Study of the Pharmacokinetics of Golimumab in Chinese Male Subjects | Centocor, Inc. | Phase 1 | Completed | Healthy Adult Chinese Males | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01288157) |
| December 24, 2010 | NCT01266811 | A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple... | Centocor, Inc. | Phase 3 | Withdrawn | Multiple Myeloma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01266811) |
| December 13, 2010 | NCT01258777 | A Study of the Pharmacokinetics of Golimumab in Japanese and Caucasian Male Subjects | Centocor, Inc. | Phase 1 | Completed | Healthy Volunteers | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01258777) |
| November 25, 2010 | NCT01248793 | Study of the Safety and Efficacy of Golimumab in Chinese Patients With Ankylosing Spondylitis | Centocor, Inc. | Phase 3 | Completed | Ankylosing Spondylitis | 213 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01248793) |
| November 25, 2010 | NCT01248780 | Study of Subcutaneous Golimumab in Chinese Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy | Centocor, Inc. | Phase 3 | Completed | Rheumatoid Arthritis | 264 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01248780) |
| September 20, 2010 | NCT01204996 | A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors | Centocor, Inc. | Phase 1 | Completed | Cancer | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01204996) |
| September 6, 2010 | NCT01195207 | A Phase 1 Study of CNTO 3157 in Healthy Volunteers and Patients With Asthma | Centocor, Inc. | Phase 1 | Completed | Asthma | 79 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01195207) |
| March 5, 2010 | NCT01081704 | A Study of the Pharmacokinetics of Ustekinumab in Chinese Male Subjects | Centocor, Inc. | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01081704) |
| March 5, 2010 | NCT01081691 | A Study Evaluating Intravenous and Subcutaneous Administration of a Human Monoclonal Antibody (CNTO 5825) in Healthy Volunteers | Centocor, Inc. | Phase 1 | Completed | Healthy | 64 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01081691) |
| November 6, 2009 | NCT01008995 | A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With Psoriasis | Centocor, Inc. | Phase 3 | Completed | Psoriasis | 322 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01008995) |
| September 9, 2009 | NCT00973479 | An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate... | Centocor, Inc. | Phase 3 | Completed | Arthritis, Rheumatoid | 592 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00973479) |
| August 10, 2009 | NCT00955279 | A Study to Evaluate the Safety and Effectiveness of Ustekinumab or Golimumab Administered Subcutaneously (SC) in Patients With Sarcoidosis | Centocor, Inc. | Phase 2 | Completed | Sarcoidosis | 173 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00955279) |
| June 22, 2009 | NCT00925574 | A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With Psoriasis | Centocor, Inc. | Phase 1 | Completed | Psoriasis | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00925574) |
| April 16, 2009 | NCT00882726 | A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of CNTO 3649 in Healthy Adults and Patients With Type 2 Diabetes Mellitus | Centocor, Inc. | Phase 1 | Completed | Diabetes Mellitus, Type 2 | 133 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00882726) |
| February 16, 2009 | NCT00844909 | A Study of the Safety and How the Body Effects a Drug CNTO 136 in Healthy Male Japanese and Caucasian Volunteers | Centocor, Inc. | Phase 1 | Completed | Healthy | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00844909) |
| February 11, 2009 | NCT00841191 | A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors | Centocor, Inc. | Phase 1/2 | Completed | Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Head and Neck Neoplasms, Lung Neoplasms | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00841191) |
| November 6, 2008 | NCT00786201 | A Study to Evaluate the Safety and Effectiveness of CNTO 888 Administered Intravenously (IV) in Participants With Idiopathic Pulmonary... | Centocor, Inc. | Phase 2 | Completed | Pulmonary Fibrosis | 126 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00786201) |
| October 13, 2008 | NCT00771667 | A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously... | Centocor, Inc. | Phase 2 | Completed | Crohn's Disease | 526 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00771667) |
| September 5, 2008 | NCT00747344 | A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type... | Centocor, Inc. | Phase 3 | Completed | Psoriasis | 121 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00747344) |
| July 21, 2008 | NCT00718718 | A Study of Effectiveness and Safety of CNTO 136 in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy | Centocor, Inc. | Phase 2 | Completed | Arthritis, Rheumatoid | 187 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00718718) |
| May 12, 2008 | NCT00675649 | A Clinical Trial Evaluating the Safety and Effectiveness of Golimumab in Patients With Severe, Persistent Asthma | Centocor, Inc. | Phase 2 | Withdrawn | Asthma | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00675649) |
| March 26, 2008 | NCT00643526 | A Study to Test the Design, Functionality, and Ergonomic Features of the Autoinjector | Centocor, Inc. | Early phase 1 | Completed | Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Psoriasis | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00643526) |
| October 1, 2007 | NCT00537381 | An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer | Centocor, Inc. | Phase 2 | Completed | Prostatic Neoplasms | 131 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00537381) |

## By phase

| Phase | Trials |
| --- | --- |
| Early phase 1 | 1 |
| Phase 1 | 15 |
| Phase 1/2 | 3 |
| Phase 2 | 17 |
| Phase 2/3 | 1 |
| Phase 3 | 36 |
| Observational | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 69 |
| Terminated | 4 |
| Withdrawn | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Arthritis, Rheumatoid | 14 |
| Psoriasis | 10 |
| Crohn Disease | 8 |
| Arthritis, Psoriatic | 5 |
| Spondylitis, Ankylosing | 4 |
| Neoplasms | 4 |
| Multiple Myeloma | 3 |
| Asthma | 3 |
| Colitis, Ulcerative | 3 |
| Prostatic Neoplasms | 3 |
| Pulmonary Disease, Chronic Obstructive | 2 |
| Sarcoidosis | 2 |
| Pancreatic Neoplasms | 2 |
| Spondylarthritis | 2 |
| Spondylarthropathies | 2 |
| Angina, Unstable | 2 |
| Skin Diseases | 1 |
| Neoplasms, Plasma Cell | 1 |
| Multiple Sclerosis | 1 |
| Retinitis Pigmentosa | 1 |
| Myocardial Infarction | 1 |
| Ovarian Neoplasms | 1 |
| Colorectal Neoplasms | 1 |
| Head and Neck Neoplasms | 1 |
| Lung Neoplasms | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Haitian restaurants in the United States](https://specstream.ai/data/businesses/haitian-restaurants/united-states)
- [Medical law firms in the United States](https://specstream.ai/data/businesses/medical-law-firms/united-states)
- [Property management companies in the United States](https://specstream.ai/data/businesses/property-management-companies/united-states)
- [Tobacco companies in the United States](https://specstream.ai/data/businesses/tobacco-companies/united-states)
- [B2B audio visual production companies in the United States](https://specstream.ai/data/businesses/b2b-audio-visual-production-companies/united-states)
- [College counseling companies in the United States](https://specstream.ai/data/businesses/college-counseling-companies/united-states)
